Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; a… Read more
Valbiotis SAS (ALVAL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.333x
Based on the latest financial reports, Valbiotis SAS (ALVAL) has a cash flow conversion efficiency ratio of -0.333x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.92 Million) by net assets (€11.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Valbiotis SAS - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Valbiotis SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Valbiotis SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valbiotis SAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SD Standard Drilling PLC
OL:SDSD
|
0.153x |
|
MotorK Ltd
AS:MTRK
|
-0.020x |
|
Coraza Integrated Technology Bhd
KLSE:0240
|
0.127x |
|
Lion Copper and Gold Corp
OTCQB:LCGMF
|
-0.514x |
|
Ledlink Optics
TWO:5230
|
0.045x |
|
Malaysia Steel Works KL Bhd
KLSE:5098
|
0.065x |
|
UNITEKNO Co.Ltd
KQ:241690
|
-0.002x |
|
Mustgrow Biologics Corp
OTCQB:MGROF
|
-0.108x |
Annual Cash Flow Conversion Efficiency for Valbiotis SAS (2015–2024)
The table below shows the annual cash flow conversion efficiency of Valbiotis SAS from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €10.37 Million | €-11.54 Million | -1.113x | -170.73% |
| 2023-12-31 | €19.60 Million | €-8.06 Million | -0.411x | +40.47% |
| 2022-12-31 | €13.31 Million | €-9.19 Million | -0.690x | -37.31% |
| 2021-12-31 | €14.23 Million | €-7.16 Million | -0.503x | -232.07% |
| 2020-12-31 | €7.07 Million | €2.69 Million | 0.381x | +163.19% |
| 2019-12-31 | €8.21 Million | €-4.95 Million | -0.603x | +1.80% |
| 2018-12-31 | €7.41 Million | €-4.55 Million | -0.614x | -186.99% |
| 2017-12-31 | €10.16 Million | €-2.17 Million | -0.214x | +90.81% |
| 2016-12-31 | €369.00K | €-858.00K | -2.325x | +73.80% |
| 2015-12-31 | €80.00K | €-710.00K | -8.875x | -- |